Section Review: Biologicals & Immunologicals: Gene therapy for haemophilia

References

• HOYER LW: Hemophilia A. New Engl. J. Med. (1994) 330(1):38–47. Excellent review of haemophilia A and factor VIII.
   Google Scholar
• THOMPSON AR: Structure, function, and molecular de- ..fects of factor IX. Blood (1986) 67(3):565–572.Excellent review of factor IX.
   Google Scholar
• FURIE B, FURIE BC: Molecular and cellular biology of asblood coagulation. New Engl. J. Med. (1992) 326(12):800–806. Excellent review of blood coagulation and clotting factors.
   Google Scholar
• Prevention and control of haemophilia: Memorandum from a joint WHO/WFH meeting. Bull. World Health O. (1991) 69(1):17–26.
   PubMed Web of Science ®Google Scholar
• LIMENTANI SA, ROTH DA, FURIE BC, FURIE B: Recombi-nant blood clotting proteins for hemophilia therapy. Seminars in Thrombosis and Hemostasis 19(1):62–72.
   Google Scholar
• BRETTLER DB, LEVINE PH: Factor concentrates for treat-ment of hemophilia: Which one to choose? Blood (1989) 73(8):2067–2073_
   Google Scholar
• PIERCE GF, LUSHER JM, BROWNSTEIN AP, GOLDSMITH JC, KESSLER CM: The use of purified clotting factor concen-trates in hemophilia. JAMA (1989) 261(23):3434–3438.
   PubMed Web of Science ®Google Scholar
• CHOO KH, GOULD KG, REES DJG, BROWNLEE GG: Mo-lecular cloning of the gene for human anti-haemophilic factor IX. Nature (1982) 299:178–180.
   PubMed Web of Science ®Google Scholar
• KURACHI K, DAVIE EW : Isolation and characterization of a cDNA coding for human factor IX. Proc. Natl. Acad. Sci. USA (1982) 79:6461–6464.
   PubMed Web of Science ®Google Scholar
• ANSON DS, CHOO ICH, REES DJG, GIANNELLI F, GOULD K, HUDDLESTON JA, BROWNLEE GG: The gene structure of human anti-haemophilic factor IX. EMBO J. (1984) 3(5):1053–1060.
   PubMed Web of Science ®Google Scholar
• KURACHI K, FURUKAWA M, YAO SN: Biology of factor IX. Blood Coagulation and Fibrinolysis (1993) 4:953–972.
   PubMed Web of Science ®Google Scholar
• WOOD WI, CAPON DJ, SIMONSEN CC, EATON DL, GIT-SCHIER J, KEYT B, SEEBURG PH, SMITH DH, HOLLING-SHEAD P, WION KL, DELWART E, TUDDENHAM EGD, VEHAR GA, LAWN RM: Expression of active human factor VIII from recombinant DNA clones. Nature (1984) 312:330–337.
   PubMed Web of Science ®Google Scholar
• VEHAR GA, KEYT B, EATON D, RODRIGUEZ H, O'BRIENP, ROTBLAT F, OPPERMANN H, KECK R, WOOD WI, HARKINS RN, TUDDENHAM EGD, LAWN RM, CAPON DJ: Structure of human factor VIII Nature (1984) 312:337–342.
   Google Scholar
• TOOLE JJ, KNOPF JL, WOZNEY JM, SULTZMAN IA, BUECKER JL, PITTMAN DD, KAUFMAN RJ, BROWN E, SHOEMAKER C, ORR EC, AMPHLE'rT GW, FOSTER DUB, COE ML, KNUTSON GJ, FASS DN, HEWICK RM: Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature (1984) 312:342–347.
   PubMed Web of Science ®Google Scholar
• KAUFMAN RJ: Biological regulation of factor VIII activity. Ann. Rev. Med. (1992) 43:325–339.
   PubMed Web of Science ®Google Scholar
• VEHAR GA, LAWN RM, TUDDENHAM EGD, WOOD WI: Factor VIII and factor V: Biochemistry and pathophysi-ology. In: The Metabolic Basis of Inherited Diseases. Scriver CR, Beaudet AL, Sly WS, Vale D (Eds.). McGraw-Hill, New York (1989).
   Google Scholar
• HEDNER U, DAVIE EW: Introduction to hemostasis and the vitamin K-dependent coagulation factors. In: The Metabolic Basis of Inherited Diseases. Scriver CR, Beaudet AL, Sly WS, Vale D (Eds.). McGraw-Hill, New York (1989).
   Google Scholar
• GILBOA E, EGLITIS MA, KANTOFF PW, ANDERSON WF: Transfer and expression of cloned genes using retrovi-ral vectors. BioTechniques (1986) 4(6):504–512.
   Web of Science ®Google Scholar
• EGUTIS MA, ANDERSON WF: Retroviral vectors for intro-duction of genes into mammalian cells. BioTechniques (1988) 6(7):608–614.
   PubMed Web of Science ®Google Scholar
• MB I FR AD, ROSMAN GJ: Improved retroviral vectors for gene transfer and expression. BioTechniques (1989) 7(9):980–990.
   PubMed Web of Science ®Google Scholar
• BERKNER KL: Development of adenovirus vectors for the expression of heterologous genes. BioTechniques (1988) 6(7):616–629.
   PubMed Web of Science ®Google Scholar
• STRATFORD-PEFtRICAUDET LD, PERRICAUDET M: Gene therapy: The advent of adenovirus. In: Gene Therapeu-tics: Methods and Applications of Direct Gene Transfer. Wolff JA (Ed.). Birkhauser, Boston (1994).
   Google Scholar
• PALMER TD, THOMPSON AR, MILLER AD: Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. Blood (1989) 73(4:438–445.
   PubMedGoogle Scholar
• SCHARFMANN R, AXELROD JH, VERMA IM: Long-term invivo expression of retrovirus mediated gene transfer in mouse fibroblast implants. Proc. Natl. Acad. Sci. USA (1991) 88:4626–4630.
   PubMed Web of Science ®Google Scholar
• YAO SN, WILSON JM, NABEL EG, KURACHI S, HACHIYAHL, KURACHI K: Expression of human factor IX in rat capillary endothelial cells: Toward somatic gene ther-apy for hemophilia B. Proc. Natl. Acad. Sci. USA (1991) 88:8101–8105.
   PubMed Web of Science ®Google Scholar
• GERRARD AJ, HUDSON DL, BROWNLEE GG, WATT FM: Towards gene therapy for haemophilia B using primary human keratinocytes. Nature Genetics (1993) 3:180–183.
   PubMed Web of Science ®Google Scholar
• DAI Y, ROMAN M, NAVIAUX RK, VERMA IM: Gene therapy In primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo. Proc. Natl. Acad. Sci. USA (1992) 89:10892–10895.
   PubMed Web of Science ®Google Scholar
• YAO SN, SMITH KJ, KURACHI K: Primary myoblast-me-diated gene transfer: persistent expression of human factor IX in mice. Gene Therapy (1994) 1:99–107.
   PubMed Web of Science ®Google Scholar
• LIU HG, OFOSU FA, CHANG PL: Expression of human factor IX by microencapsulated recombinant fi-broblasts. Hum. Gene Ther. (1993) 4:291–301.
   PubMed Web of Science ®Google Scholar
• HORTELANO G, AL-HENDY A, OFOSU F, CHANG PL: Delivery of factor IX in mice from implantable micro-capsules as a model for gene therapy of hemophilia B. J. Cell. Biochem. (1995) Supplement 21A:365 (Abstract C6–119).
   Google Scholar
• BRAUKER J, DWARKI V, CARR-BRENDEL V, NIJJAR T, VERGOTH C, CHEN R, COHEN L, DANOS 0, MULLIGAN R, JOHNSON RC: Expression of human factor IX in rats and mice from cells implanted within an immunoisolation device. J. Cell. Biochem. (1995) Supplement 21A:375 (Ab-stract C6–202).
   Google Scholar
• ZHOU JM, QIU XF, LU DR, LU JY, XUE JL, HSUEH JL: Long-term expression of human factor IX cDNA in rabbits. Science in China (Series B) (1993) 36:1333–1341.
   PubMedGoogle Scholar
• LU DR, ZHOU JM, ZHENG B, HSEUH JL: Stage I clinical trial of gene therapy for hemophilia B. Science in China (Series B) (1993) 36:1342–1351.
   PubMedGoogle Scholar
• KOEBERL DD, HALBERT CL, KRUMM A, MILLER AD: Se-quences within the coding regions of dotting factor VIII and CFTR block transcriptional elongation. Hum. Gene Ther. (1995) 6:469–479.
   PubMed Web of Science ®Google Scholar
• HOEBEN RC, FALLAUX FJ, CRAMER SJ, VAN DEN WOLLEN-BERG JM, VAN ORMONDT H, BRIET E, VAN DER EB AJ: Expression of the blood-clotting factor-VM cDNA is repressed by a transcriptional silencer located in its coding region. Blood (1995) 85(9):2447–2454.
   PubMed Web of Science ®Google Scholar
• DWARKI VJ, BELLONI P, MBAR T, SMITH J, COUTO L, RABIER M, CLIFF S, BERNS A, COHEN LK: Gene therapy for hemophilia A: Production of therapeutic levels of human factor VM in vivo in mice. Proc. Natl. Acad. Sci. USA (1995) 92:1023-1027. First demonstration of retroviral-mediated expression of human factor VIII in viva
   Google Scholar
• HOEBEN RC, FALLAUX FJ, VAN TILBURG NH, CRAMER SJ,VAN ORMONDT H, BRIET E, VAN DER EB AJ: Toward gene therapy for hemophilia A: Long-term persistence of factor VTR-secreting fibroblasts after transplantation Into immunodeficient mice. Hum. Gene Ther. (1993) 4:179–186.
   PubMed Web of Science ®Google Scholar
• HOEBEN RC, EINERHAND MPW, BRIET E, VAN ORMONDTH, VALERIO D, VAN DER EB AJ: Toward gene therapy in hemophilia A: Retrovirus-mediated transfer of a factor VM gene into muritte hemopoietic progenitor cells. Thromb. Haemost. (1992) 67:341–345.
   PubMed Web of Science ®Google Scholar
• ZATLOUKAL K, COTFEN M, BERGER M, SCHMIDT W, WAGNER E, BIRNSTIEL ML: In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc. Natl. Acad. Sci. USA (1994) 91:5148–5152.
   PubMed Web of Science ®Google Scholar
• SMITH TAG, MEHAFFEY MG, KAYDA DB, SAUNDERS JM,• YEI S, TRAPNELL BC, MCCLELLAND A, KALEKO M: Ade-novirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genetics (1993) 5:397-402. First demonstration of adenoviral vector-mediated expression of human factor IX in vivo.
   Google Scholar
• KALEKO M, KAYDA D, SAKHUJA K, MEHAFFEY M, MCCLEL- LAND A: Genomic sequences increase adenoviral vec-tor-mediated factor IX expression 1,900 fold and enable sustained expression in vivo. J. Cell. Biochem. (1995) Supplement 21A:366 (Abstract C6-121). Demonstrates that genomic sequences dramatically increase expres-sion of human factor IX from an adenoviral vector.
   Google Scholar
• KAY MA, LANDEN CN, ROTHENBERG SR, TAYLOR LA, LELAND F, WIEHLE S, FANG B, BELLINGER D, FINEGOLD M, THOMPSON AR, READ M, BRINKHOUS KM, WOO SLC: In vivo hepatic gene therapy: Complete albeit transient correction of factor IX defidency in hemophilia B dogs. Proc. Natl. Acad. Sci. USA (1994) 91:2353-2357. Demonstrates correction of phenotype in haemophilia B dog.
   Google Scholar
• FANG B, EISENSMITH RC, WANG H, KAY MA, CROSS RE, LANDEN CN, GAVIN G, BELLINGER DA, READ MS, HU PC, BRINKHOUS KM, WOO SLC: Gene therapy for hemo-philia B: Host immunosuppression prolongs the thera-peutic effect of adenovirus-mediated gene transfer. J. Cell. Biochem. (1995) Supplement 21A:363 (Abstract C6–109).
   Google Scholar
• DAI Y, SCHWARZ EM, GU D, ZHANG WW, SARVETNICK N,VERMA IM: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Toleriza-don of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA (1995) 92:1401–1405.
   PubMed Web of Science ®Google Scholar
• CONNELLY S, SMITH TAG, DHIR G, GARDNER JM, MEHAF- FEY M, ZARET KS, MCCLELLAND A, KALEKO M: In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum. Gene Ther. (1995) 6:185-193. First demonstration of adenoviral vector-mediated expression of human factor VIII in vivo.
   Google Scholar
• CONNELLY S, GARDNER JM, MCCLELLAND A, KALEKO M: Sustained expression of physiological levels of func-tional human factor VM in mice. J. Cell. Biochem. (1995) Supplement 21A:362 (Abstract C6–105).
   Google Scholar
• KAY MA, ROTHENBERG S, LANDEN CN, BELLINGER DA, LELAND F, TOMAN C, FINEGOLD M, THOMPSON AR, READ MS, BRINKHOUS KM, WOO SLC: In vivo gene therapy of hemophilia B: Sustained partial correction in factor DE-deficient dogs. Science (1993) 262:117–119.
   PubMed Web of Science ®Google Scholar
• MIYANOHARA A, JOHNSON PA, ELAM RL, DAI Y, WITZTUM JL, VERMA IM, FRIEDMANN T: Direct gene transfer to the liver with herpes simplex virus type 1 vectors: Transient production of physiologically rele-vant levels of circulating factor IX. The New Biologist (1992) 4(3):238–246.
   PubMedGoogle Scholar
• KOTIN RM: Prospects for the use of adeno-associatedvirus as a vector for human gene therapy. Hum. Gene Ther. (1994) 5:793–801.
   PubMed Web of Science ®Google Scholar
• PERALES JC, FERKOL T, BEEGEN H, RATNOFF OD, HAN-SON RW: Gene transfer in vivo: Sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc. Natl. Acad. Sci. USA (1994) 91:4086–4090.
   PubMed Web of Science ®Google Scholar
• LOZIER JN, THOMPSON AR, HU PC, READ M, BRINKHOUSKM, HIGH ER, CURIEL DT: Efficient transfection of pri-mary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes. Hum. Gene Ther. (1994) 5:313–322.
   PubMed Web of Science ®Google Scholar
• PALMER TD, ROSMAN GJ, OSBORNE RA, MILLER AD: Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. USA (1991) 88:1330–1334.
   PubMed Web of Science ®Google Scholar
• STRATFORD-PERRICAUDET LD, LEVRERO M, CHASSE J, PERRICAUDET M, BRIAND P: Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum. Gene Ther. (1990) 1:241–256.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT JF, YANG Y, STRATFORD-PERRICAUDET LD,ALLEN ED, KOZARSKY K, PERRICAUDET M, YANKASKAS JR, WILSON JM: Direct gene transfer of human CF111 into human bronchial epithelia of xenografts with El-de-leted adenoviruses. Nature Genetics (1993) 4:27–34.
   PubMed Web of Science ®Google Scholar
• YANG Y, NUNES FA, BERENCSI K, FURTH EE, GONCZOL E, WILSON JM: Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA (1994) 91:4407–4411.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT JF, YE X, DORANZ B, WILSON JM: Ablation of E2A in recombinant adenoviruses improves trans-gene persistence and decreases inflatrunatory response In mouse liver. Proc. Natl. Acad. Sci. USA (1994) 91:6196-6200. Demonstrates strategy to prevent CTL response against cells transduced with an adenoviral vector.
   Google Scholar